Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures

Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures

Abstract Objective Eslicarbazepine acetate (ESL) is a once‐daily (QD), oral anti‐seizure medication for the treatment of focal (partial‐onset) seizures. Here, we evaluate risk factors for the development of psychiatric treatment‐emergent adverse events (TEAEs) in clinical trials of adjunctive ESL in...

Full description

Bibliographic Details
Main Authors: Hamada Altalib, Todd Grinnell, David Cantu, Fábio Ikedo, Mariana Vieira, Yi Zhang, David Blum
Format: Article
Language:English
Published: Wiley 2022-12-01
Series:Epilepsia Open
Subjects:
anxiety
depression
eslicarbazepine acetate
focal seizures
psychiatric
psychotropic
Online Access:https://doi.org/10.1002/epi4.12635

Similar Items

Similar Items